Copyright © 2021. Inderes Oyj. All rights reserved.
Etsi
Käyttäjätili

Hei anonyymi!

Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.

Luo tili

Onko sinulla jo Inderes-tili?

Cantargia

Analyytikko

Foorumi

Tästä Foorumille

Sisäpiirin kaupat

Nettovaikuttavuus

Artikkeli
Yhtiöjulkaisu
Tiedotteet
Cantargia publishes ASCO 2023 poster on promising nadunolimab efficacy in non-small cell lung cancer
4.6.
2023

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today presented interim efficacy data for 39 non-small cell lung cancer (NSCLC) patients treated with nadunolimab (CAN04) and platinum-based chemotherapy as a poster at the ASCO Annual Meeting 2023 (ASCO 2023), and on the Cantargia webpage. Efficacy of the combination therapy was well above historical data for chemotherapy alone, including two patients with complete response.

Tiedotteet
Cantargia announces updates to the management team
1.6.
2023

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced that Dr. David Liberg, member of Cantargia’s management team, has been promoted to Chief Scientific Officer (CSO). Additionally, Patrik Renblad will formally take on the role as Chief Financial Officer (CFO) starting June 15, 2023.

Tiedotteet
Cantargia to present promising nadunolimab efficacy in non-small cell lung cancer at ASCO 2023, including two complete responses
26.5.
2023

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported it will present updated interim efficacy data for 39 non-small cell lung cancer (NSCLC) patients treated with nadunolimab (CAN04) and platinum-based chemotherapy at the ASCO Annual Meeting (ASCO 2023) in Chicago on June 4, 2023. The results have demonstrated improvement since the previous update with objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) comparing very favorably to historical data for chemotherapy alone.

Tiedotteet
Redeye: Cantargia Q1 2023 - Strong results with IL1RAP-high patients
24.5.
2023

Redeye reviews Cantargia’s first quarter report. Since our last update (Q4 2022), important results have been published at the AACR meeting, demonstrating the superior efficacy of nadunolimab in pancreatic cancer patients with high levels of IL1RAP. The next step in the development of nadunolimab in pancreatic cancer will be a phase IIb study instead of the registrational Precision Promise. However, due to the longer development needed and other factors we lower our Base Case.

Tiedotteet
Annual General Meeting in Cantargia AB (publ)
23.5.
2023

Cantargia’s Annual General Meeting on 23 May 2023 resolved in accordance with the following:

Tiedotteet
Cantargia publishes interim report for the first quarter of 2023
23.5.
2023

Cantargia AB’s (”Cantargia”) interim report for the first quarter of 2023 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.

Significant events in the first quarter

Tiedotteet
Cantargia intensifies development of nadunolimab in pancreatic cancer with new controlled phase IIb clinical trial following strong phase IIa efficacy results
15.5.
2023

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced intensified development of its lead asset, the antibody nadunolimab (CAN04), in pancreatic cancer (PDAC), through a new randomized controlled phase IIb trial. This trial will build on the strong interim phase IIa efficacy results presented at the AACR Annual Meeting 2023. Regulatory submission is planned for H2 2023 with top line data planned for 2025. Financial resources previously earmarked for the Precision Promise trial, will be used for this phase IIb trial.

Tiedotteet
Invitation to presentation of Cantargia’s report for the first quarter of 2023 on May 23 at 10.00 a.m. CEST
9.5.
2023

Cantargia AB will publish the company’s report for the first quarter of 2023 on Tuesday, May 23, 2023 at 08:30 a.m. CEST.

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on May 23, at 10:00 a.m. CEST, where the company management will present Cantargia and comment on the quarterly report for the first quarter 2023, followed by a Q&A-session.

Tiedotteet
Cantargia publishes annual report for the financial year 2022
27.4.
2023

Cantargia AB's annual report for the financial year 2022 is now available on the company's website (www.cantargia.com)  and at the company's office, address Scheelevägen 27 in Lund.

Tiedotteet
Notice of annual general meeting in Cantargia AB (publ)
24.4.
2023

The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Tuesday, 23 May 2023, at 16.00 CEST at Ideon Gateway, Scheelevägen 27, Lund, Sweden.

Right to participate and notice
Shareholders who wish to participate in the meeting must:

Cantargia